Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.34
USD
|
+6.35%
|
|
+2.29%
|
+14.53%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
119.3
|
132.5
|
164.1
|
67.41
|
73.02
|
100.1
|
-
|
-
|
Enterprise Value (EV)
1 |
101.9
|
116.2
|
133.6
|
19.16
|
73.02
|
78.88
|
112.5
|
128.7
|
P/E ratio
|
-3.58
x
|
-7.03
x
|
275
x
|
-2.04
x
|
-2.21
x
|
-2.55
x
|
-2.31
x
|
-2.31
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
54.9
x
|
16.8
x
|
5.55
x
|
50.8
x
|
8.88
x
|
36.5
x
|
13.6
x
|
3.81
x
|
EV / Revenue
|
46.9
x
|
14.7
x
|
4.52
x
|
14.4
x
|
8.88
x
|
28.8
x
|
15.3
x
|
4.9
x
|
EV / EBITDA
|
-3,385,883
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-3,760,800
x
|
-
|
-12,451,964
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,150
|
48,354
|
59,667
|
60,191
|
62,409
|
74,731
|
-
|
-
|
Reference price
2 |
2.900
|
2.740
|
2.750
|
1.120
|
1.170
|
1.340
|
1.340
|
1.340
|
Announcement Date
|
3/11/20
|
3/10/21
|
3/10/22
|
3/9/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.173
|
7.894
|
29.58
|
1.327
|
8.226
|
2.743
|
7.358
|
26.26
|
EBITDA
|
-30.09
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-30.3
|
-17.94
|
-0.627
|
-30.28
|
-24.84
|
-34.98
|
-37.44
|
-32.52
|
Operating Margin
|
-1,394.57%
|
-227.2%
|
-2.12%
|
-2,281.61%
|
-302.02%
|
-1,275.36%
|
-508.85%
|
-123.81%
|
Earnings before Tax (EBT)
1 |
-30.77
|
-18.21
|
0.376
|
-32.95
|
-32.48
|
-39.72
|
-44.99
|
-48.09
|
Net income
1 |
-30.77
|
-18.21
|
0.376
|
-32.95
|
-32.48
|
-39.65
|
-43.04
|
-44.68
|
Net margin
|
-1,416.01%
|
-230.68%
|
1.27%
|
-2,482.82%
|
-394.91%
|
-1,445.75%
|
-585.05%
|
-170.13%
|
EPS
2 |
-0.8100
|
-0.3900
|
0.0100
|
-0.5500
|
-0.5300
|
-0.5260
|
-0.5800
|
-0.5800
|
Free Cash Flow
|
-27.09
|
-
|
-10.73
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-1,246.8%
|
-
|
-36.29%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/10/21
|
3/10/22
|
3/9/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
3.074
|
25.69
|
0.347
|
0.384
|
0.266
|
0.33
|
0.004
|
1.018
|
0.859
|
6.345
|
0.6812
|
0.6842
|
0.6872
|
0.6902
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.889
|
18.71
|
-7.646
|
-7.837
|
-6.724
|
-8.07
|
-7.605
|
-7.27
|
-7.054
|
-2.915
|
-8.561
|
-8.723
|
-8.5
|
-8.602
|
-
|
Operating Margin
|
-159.04%
|
72.83%
|
-2,203.46%
|
-2,040.89%
|
-2,527.82%
|
-2,445.45%
|
-190,125%
|
-714.15%
|
-821.19%
|
-45.94%
|
-1,256.66%
|
-1,274.83%
|
-1,236.74%
|
-1,246.14%
|
-
|
Earnings before Tax (EBT)
1 |
-4.887
|
18.71
|
-7.644
|
-7.813
|
-7.827
|
-9.663
|
-9.28
|
-9.106
|
-9.267
|
-4.832
|
-9.964
|
-10.14
|
-9.925
|
-10.01
|
-
|
Net income
1 |
-4.887
|
18.71
|
-7.644
|
-7.813
|
-7.827
|
-9.663
|
-9.28
|
-9.106
|
-9.267
|
-4.832
|
-10
|
-10.22
|
-9.903
|
-9.801
|
-
|
Net margin
|
-158.98%
|
72.83%
|
-2,202.88%
|
-2,034.64%
|
-2,942.48%
|
-2,928.18%
|
-232,000%
|
-894.5%
|
-1,078.81%
|
-76.15%
|
-1,468.24%
|
-1,493.14%
|
-1,440.9%
|
-1,419.89%
|
-
|
EPS
2 |
-0.0800
|
0.3100
|
-0.1300
|
-0.1300
|
-0.1300
|
-0.1600
|
-0.1500
|
-0.1500
|
-0.1500
|
-0.0800
|
-0.1380
|
-0.1360
|
-0.1260
|
-0.1240
|
-0.1100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/10/22
|
5/11/22
|
8/9/22
|
11/9/22
|
3/9/23
|
5/12/23
|
8/14/23
|
11/13/23
|
3/12/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
12.3
|
28.6
|
Net Cash position
1 |
17.4
|
16.3
|
30.4
|
48.3
|
-
|
21.3
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-27.1
|
-
|
-10.7
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.03
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
1.15%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/10/21
|
3/10/22
|
3/9/23
|
3/12/24
|
-
|
-
|
-
|
Last Close Price
1.34
USD Average target price
5.4
USD Spread / Average Target +302.99% Consensus |
1st Jan change
|
Capi.
|
---|
| +14.53% | 100M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|